Compare JetBlue Airways Corporation (JBLU) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? JetBlue Airways Corporation trades at $5.34 (market cap $2.03B), while Regeneron Pharmaceuticals Inc trades at $671.56 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 34.7× JetBlue Airways Corporation's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| JBLU | REGN | |
|---|---|---|
Market Cap | $2.03B | $70.47B |
Sector | Industrials | Health |
52-Week High | $6.46 | $812.27 |
52-Week Low | $4.03 | $545.46 |
Enterprise Value | $9.19B | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.45, up 0.55% today, with technical indicators showing a neutral bias despite recent earnings misses. The airline reported a net loss of $602 million in 2025 with negative profit margins, though valuation metrics like P/S of 0.22 appear attractive. Recent news highlights expansion at Fort Lauderdale and new payment partnerships, while analyst consensus remains cautious with a $5.12 price target.
JBLU faces significant challenges with persistent losses and high debt levels, though strategic expansions and cost management efforts provide some optimism. The stock trades near analyst targets with mixed sentiment, requiring careful monitoring of upcoming Q2 2026 earnings and fuel cost trends for directional clarity.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
